Keros Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€199.78M - Cost of goods sold
€317.46K - Gross profit
€199.18M - SG&A expenses
€39.01M - R&D expenses
€160.50M - EBITDA
€6.24M - D&A
€897.47K - EBIT
€267.70K - Interest expenses
€0.00 - EBT
€23.08M - Tax expenses
€6.97M - Net income
€16.11M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€814.24K - Changes in working capital
-€1.26M - Operating cash flow
€47.22M - Capex
€1.68M - Other investing cash flow
€0.00 - Net investing cash flow
-€1.68M - Total cash dividends paid
€0.00 - Issuance of common stock
€195.78M - Debt repayment
€0.00 - Other financing cash flow
€2.85M - Net financing cash flow
€198.63M - Foreign exchange effects
€0.00 - Net change in cash
€244.18M - Cash at end of period
€593.45M - Free cash flow
€48.91M
Balance sheet
- Cash and cash equivalents
€592.21M - Cash and short-term investments
€592.21M - Total receivables
€13.57M - Inventory
€0.00 - Other current assets
€22.97M - Total current assets
€628.75M - Property, plant & equipment
€19.66M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€1.24M - Other non-current assets
€0.00 - Total non-current assets
€20.90M - Total assets
€649.65M - Accounts payable
€4.52M - Short-term debt
€1.91M - Other current liabilities
€22.55M - Total current liabilities
€29.78M - Long-term debt
€26.98M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€13.49M - Total liabilities
€43.27M - Common stock
€3.43K - Retained earnings
-€386.98M - Other equity
€0.00 - Total equity
€606.38M - Total liabilities and shareholders' equity
€649.65M
Company information
- Market capitalization
€467.33M - Employees
163 - Enterprise Value
-€142.04M
Company ratios
- Gross margin
-
99.7% Much better than peer group: -733.2% - EBITDA margin
-
3.1% Much better than peer group: -3,381.4% - EBIT margin
-
0.1% Much better than peer group: -3,496.9% - EBT margin
-
11.6% Much better than peer group: -3,445.6% - Net margin
-
8.1% Much better than peer group: -3,441.2% - ROE
-
2.7% Much better than peer group: -24.3% - ROA
-
2.5% Much better than peer group: -33.4% - Asset turnover
-
30.8% Much better than peer group: 7.8% - FCF margin
-
22.8% Much better than peer group: -2,754.2% - FCF yield
9.7% - Efficiency ratio
96.9% - Net sales per employee
-
€1.23M - Net income per employee
-
€98.82K